Healthcare provider profile · identity verified

Joanna Jensen

Nurse Practitioner · LONGVIEW, WA · NPI 1780058743

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	461	123
Levothyroxine Sodium	Levothyroxine Sodium	345	68
Furosemide	Furosemide	328	71
Oxycodone Hcl	Oxycodone Hcl	315	83
Gabapentin	Gabapentin	234	58
Eliquis	Apixaban	205	47
Potassium Chloride	Potassium Chloride	205	59
Pantoprazole Sodium	Pantoprazole Sodium	188	55
Amlodipine Besylate	Amlodipine Besylate	185	61
Tamsulosin Hcl	Tamsulosin Hcl	150	52
Mirtazapine	Mirtazapine	146	28
Metoprolol Succinate	Metoprolol Succinate	137	57
Lisinopril	Lisinopril	122	40
Sertraline Hcl	Sertraline Hcl	109	29
Metoprolol Tartrate	Metoprolol Tartrate	108	33
Trazodone Hcl	Trazodone Hcl	107	32
Losartan Potassium	Losartan Potassium	105	36
Clopidogrel	Clopidogrel Bisulfate	104	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	103	23
Omeprazole	Omeprazole	103	45
Glipizide Er	Glipizide	90	12
Metformin Hcl	Metformin Hcl	90	22
Famotidine	Famotidine	82	26
Pregabalin	Pregabalin	72	14
Carvedilol	Carvedilol	71	22
Duloxetine Hcl	Duloxetine Hcl	70	23
Tramadol Hcl	Tramadol Hcl	69	17
Escitalopram Oxalate	Escitalopram Oxalate	65	15
Myrbetriq	Mirabegron	63	suppressed
Xarelto	Rivaroxaban	60	suppressed
Metformin Hcl Er	Metformin Hcl	57	13
Januvia	Sitagliptin Phosphate	56	suppressed
Hydralazine Hcl	Hydralazine Hcl	54	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	54	22
Memantine Hcl	Memantine Hcl	52	12
Ondansetron Hcl	Ondansetron Hcl	51	14
Lactulose	Lactulose	49	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	48	19
Buspirone Hcl	Buspirone Hcl	47	11
Donepezil Hcl	Donepezil Hcl	47	21
Levetiracetam	Levetiracetam	47	13
Pravastatin Sodium	Pravastatin Sodium	45	suppressed
Jardiance	Empagliflozin	43	12
Fluoxetine Hcl	Fluoxetine Hcl	41	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	18
Quetiapine Fumarate	Quetiapine Fumarate	39	12
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Allopurinol	Allopurinol	38	14
Ondansetron Odt	Ondansetron	36	suppressed
Morphine Sulfate Er	Morphine Sulfate	35	suppressed
Glipizide	Glipizide	34	suppressed
Tizanidine Hcl	Tizanidine Hcl	33	suppressed
Baclofen	Baclofen	32	12
Ezetimibe	Ezetimibe	32	suppressed
Midodrine Hcl	Midodrine Hcl	32	suppressed
Montelukast Sodium	Montelukast Sodium	31	suppressed
Risperidone	Risperidone	29	suppressed
Spironolactone	Spironolactone	29	13
Finasteride	Finasteride	27	11
Lagevrio (Eua)	Molnupiravir	27	26
Oxybutynin Chloride Er	Oxybutynin Chloride	27	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	25	19
Alendronate Sodium	Alendronate Sodium	25	11
Cephalexin	Cephalexin	25	16
Warfarin Sodium	Warfarin Sodium	25	14
Carbidopa-Levodopa	Carbidopa/Levodopa	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Bumetanide	Bumetanide	23	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Lithium Carbonate	Lithium Carbonate	23	suppressed
Methenamine Hippurate	Methenamine Hippurate	23	suppressed
Olanzapine	Olanzapine	23	suppressed
Dantrolene Sodium	Dantrolene Sodium	22	suppressed
Farxiga	Dapagliflozin Propanediol	22	suppressed
Digoxin	Digoxin	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	14
Oxcarbazepine	Oxcarbazepine	21	suppressed
Admelog	Insulin Lispro	20	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	20	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	20	suppressed
Nystatin	Nystatin	20	12
Prednisone	Prednisone	20	suppressed
Divalproex Sodium	Divalproex Sodium	18	suppressed
Humalog	Insulin Lispro	18	suppressed
Latanoprost	Latanoprost	18	suppressed
Valsartan	Valsartan	18	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	16	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	16	suppressed
Lorazepam	Lorazepam	16	11
Cefdinir	Cefdinir	15	12
Divalproex Sodium Er	Divalproex Sodium	15	suppressed
Fentanyl	Fentanyl	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Atenolol	Atenolol	14	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	14	suppressed
Linzess	Linaclotide	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Leflunomide	Leflunomide	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Cilostazol	Cilostazol	12	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	11	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Enoxaparin Sodium	Enoxaparin Sodium	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Methimazole	Methimazole	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error